Dr Hui-Ming Lin

Hui-Ming completed her PhD degree at the University of Auckland in 2010. Her PhD thesis was about the metabolomic analysis of the interleukin-10 knockout mouse model of inflammatory bowel disease. Prior to her PhD studies, she was an Assistant Research Fellow in the Cancer Genetics Laboratory, Unive
Senior Research Officer

Hui-Ming completed her PhD degree at the University of Auckland in 2010. Her PhD thesis was about the metabolomic analysis of the interleukin-10 knockout mouse model of inflammatory bowel disease.

Prior to her PhD studies, she was an Assistant Research Fellow in the Cancer Genetics Laboratory, University of Otago, New Zealand, from 2004-2006.

Her current research at the Garvan Institute focuses on identifying biomarkers and new therapeutic strategies to overcome chemotherapy resistance in metastatic prostate cancer.

Research Interests

biomarker discovery
predicting and improving therapeutic response in prostate cancer
role of microRNAs in therapeutic response
lipid metabolism in prostate cancer

Education

2010 - PhD (Molecular Medicine), University of Auckland, New Zealand
2003 - MSc (Biochemistry), University of Canterbury, New Zealand
2000 - BSc (Biochemistry), University of Canterbury, New Zealand

Selected Publications

Lin H-M, Lee BY, Castillo L, Spielman C, Grogan J, Yeung NK, Kench JG, Stricker PD, Haynes AM, Centenera MM, Butler LM, Shreeve SM, Horvath LG, Daly RJ. Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer. Prostate. 2018; 78(4):308-317 

Lin H-M, Mahon KL, Weir JM, Mundra PA, Spielman C, Briscoe K, Gurney H, Mallesara G, Marx G, Stockler MR, PRIMe Consortium, Parton RG, Hoy AJ, Daly RJ, Meikle PJ, Horvath LG. A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer. Int J Cancer. 2017; 141 (10):2112-2120

Lin H-M, Mahon KL, Spielman C, Gurney H, Mallesara G, Stockler MR, Bastick P, Briscoe K, Marx G, Swarbrick A, Horvath LG. Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer. Br J Cancer. 2017; 116 (8):1002-1011

Mahon KL, Lin H-M, Castillo L, Lee BY, Lee-Ng M, Chatfield MD, Chiam K, Breit SN, Brown DA, Molloy MP, Marx GM, Pavlakis N, Boyer MJ, Stockler MR, Daly RJ, Henshall SM, Horvath LG. Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer. Br J Cancer. 2015; 112 (8):1340-1348 

Lin H-M, Castillo L, Mahon KL, Chiam K, Lee BY, Nguyen Q, Boyer MJ, Pavlakis N, Marx G, Mallesara G, Gurney H, Clark SJ, Swarbrick A, Daly RJ, Horvath LG. Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. Br J Cancer. 2014; 110(10):2462-2471

Lee BY, Hochgrafe F, Lin H-M, Castillo L, Wu J, Raftery MJ, Shreeve SM, Horvath LG, Daly RJ. Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer. Mol Cancer Ther. 2014;13(1):190-201

Lin H-M, Barnett MP, Roy NC, Joyce NI, Zhu S, Armstrong K, Helsby NA, Ferguson LR, Rowan DD. Metabolomic analysis identifies inflammatory and noninflammatory metabolic effects of genetic modification in a mouse model of Crohn’s disease. J Proteome Res. 2010;9(4):1965-1975

Person portrait

Dr Hui-Ming Lin

Research group